Prescription Drug Policy

PDABs say they’re helping patients. In reality, they’re muzzling public input and playing politics with life-saving medications.

One shot a year could transform HIV care. But unless we fix access and policy, these breakthroughs won’t reach those who need them most.

Copay accumulator policies make patients pay twice. It's 2025, and insurers are still profiting while patients go broke.

The FTC confirms PBMs are price-gouging specialty generics, raking in billions while blocking patient access to life-saving meds.

Congress faces urgent healthcare decisions before 2025—telehealth, CHC funding, and physician payments hang in the balance during lame duck.